酪氨酸激酶抑制剂在肺纤维化治疗中的研究进展

Research progress of tyrosine kinase inhibitors in the treatment of pulmonary fibrosis

肺纤维化是一种发病率高的进行性慢性肺部疾病。虽然致病途径尚未完全阐明,但其致病过程大致相近。酪氨酸激酶参与一系列对细胞稳态至关重要的信号传导途径。来自体外研究和实验动物模型的实验数据表明,酪氨酸激酶具有推动肺纤维化发生和发展的作用,并且酪氨酸激酶抑制剂在肺纤维化的动物模型中显示出良好的抗纤维化和抗炎的作用。

Objective Pulmonary fibrosis is a progressive chronic lung disease with a high incidence.Although the path of the disease has not been fully elucidated, the pathogenesis of the disease is roughly similar.Tyrosine kinases are involved in a series of signaling pathways that are critical for cell homeostasis.Substantial evidence from in vitro studies and experimental animal models suggests that tyrosine kinases play a role in promoting the development and progression of pulmonary fibrosis, and tyrosine kinase inhibitors have shown good anti-fibrosis and anti-inflammatory effect in animal models of pulmonary fibrosis.